Search research articles
Contact Us
Filters
Showing results (331-340 of 369) with videos related to
Page
of 37
Sort By:
British Journal of Cancer
|
March 5, 2002
An analysis of p53, BAX and vascular endothelial growth factor expression in node-positive rectal cancer. Relationships with tumour recurrence and event-free survival of patients treated with adjuvant chemoradiation
S Cascinu, F Graziano, V Catalano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 6, 2000
A combination of a fixed dose rate infusion of gemcitabine associated to a bolus 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)
S Cascinu, L Frontini, R Labianca, et al.
Medical Oncology (Northwood, London, England)
|
December 6, 2013
A prospective observational study to evaluate G-CSF usage in patients with solid tumors receiving myelosuppressive chemotherapy in Italian clinical oncology practice
S Barni, V Lorusso, M Giordano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 28, 2002
Thymidylate synthase protein expression in colorectal cancer metastases predicts for clinical outcome to leucovorin-modulated bolus or infusional 5-fluorouracil but not methotrexate-modulated bolus 5-fluorouracil
C Aschele, D Debernardis, R Bandelloni, et al.
Lung Cancer (Amsterdam, Netherlands)
|
March 22, 2005
Phase II trial of oral vinorelbine in combination with cisplatin followed by consolidation therapy with oral vinorelbine in advanced NSCLC
M De Lena, R Ramlau, O Hansen, et al.
Journal of Pain and Symptom Management
|
April 16, 1999
A new palliative prognostic score: a first step for the staging of terminally ill cancer patients. Italian Multicenter and Study Group on Palliative Care
M Pirovano, M Maltoni, O Nanni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 4, 2003
Weekly gemcitabine and cisplatin chemotherapy: a well-tolerated but ineffective chemotherapeutic regimen in advanced pancreatic cancer patients. A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)
S Cascinu, R Labianca, V Catalano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2000
Immunohistochemical determination of p53 protein does not predict clinical response in advanced colorectal cancer with low thymidylate synthase expression receiving a bolus 5-fluorouracil-leucovorin combination
S Cascinu, V Catalano, C Aschele, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 6, 1999
A phase II study of Tomudex alternated with methotrexate, 5-fluorouracil, leucovorin in first-line chemotherapy of metastatic colorectal cancer
S Cascinu, R R Silva, R Labianca, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 31, 2009
Activity of fulvestrant in HER2-overexpressing advanced breast cancer
J F R Robertson, G G Steger, P Neven, et al.
Page
of 37
Search research articles
Search
Showing results (331-340 of 369) with videos related to
Sort By:
Page
of 37
British Journal of Cancer
|
March 5, 2002
An analysis of p53, BAX and vascular endothelial growth factor expression in node-positive rectal cancer. Relationships with tumour recurrence and event-free survival of patients treated with adjuvant chemoradiation
S Cascinu, F Graziano, V Catalano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 6, 2000
A combination of a fixed dose rate infusion of gemcitabine associated to a bolus 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)
S Cascinu, L Frontini, R Labianca, et al.
Medical Oncology (Northwood, London, England)
|
December 6, 2013
A prospective observational study to evaluate G-CSF usage in patients with solid tumors receiving myelosuppressive chemotherapy in Italian clinical oncology practice
S Barni, V Lorusso, M Giordano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 28, 2002
Thymidylate synthase protein expression in colorectal cancer metastases predicts for clinical outcome to leucovorin-modulated bolus or infusional 5-fluorouracil but not methotrexate-modulated bolus 5-fluorouracil
C Aschele, D Debernardis, R Bandelloni, et al.
Lung Cancer (Amsterdam, Netherlands)
|
March 22, 2005
Phase II trial of oral vinorelbine in combination with cisplatin followed by consolidation therapy with oral vinorelbine in advanced NSCLC
M De Lena, R Ramlau, O Hansen, et al.
Journal of Pain and Symptom Management
|
April 16, 1999
A new palliative prognostic score: a first step for the staging of terminally ill cancer patients. Italian Multicenter and Study Group on Palliative Care
M Pirovano, M Maltoni, O Nanni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 4, 2003
Weekly gemcitabine and cisplatin chemotherapy: a well-tolerated but ineffective chemotherapeutic regimen in advanced pancreatic cancer patients. A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)
S Cascinu, R Labianca, V Catalano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2000
Immunohistochemical determination of p53 protein does not predict clinical response in advanced colorectal cancer with low thymidylate synthase expression receiving a bolus 5-fluorouracil-leucovorin combination
S Cascinu, V Catalano, C Aschele, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 6, 1999
A phase II study of Tomudex alternated with methotrexate, 5-fluorouracil, leucovorin in first-line chemotherapy of metastatic colorectal cancer
S Cascinu, R R Silva, R Labianca, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 31, 2009
Activity of fulvestrant in HER2-overexpressing advanced breast cancer
J F R Robertson, G G Steger, P Neven, et al.
Page
of 37